ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Endometrial Cancer
Squamous Cell Carcinoma

Triple Negative Breast Cancer trials near Paris, Île-de-France, FRA:

Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer (SKYLINE)

This is a phase II study, preceded by a safety run-in, with two independent cohorts (cohort A in early Triple Negative Breast...

Enrolling
Triple Negative Breast Cancer
Radiation: 68Ga-FAPI-46 PET/CT
Biological: Tumor samples analysis

Phase 2

Institut Curie

Paris, France and 1 other location

Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)

CUPCAKE is a randomized, non-comparative, multicenter, proof-of-concept phase II trial, using the Trials within Cohorts concept(1) to assess the clin...

Not yet enrolling
Triple Negative Breast Cancer
Diagnostic Test: 68Ga-FAPI-46-PET-CT
Diagnostic Test: ctDNA monitoring
Institut Curie

Paris, France and 12 other locations

Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer (ISIdE)

ISIdE is an European, multicentric study that aims to assess the efficacy of Sacituzumab Govitecan (SG) in locally advanced or metastatic triple...

Enrolling
Metastatic Breast Cancer
Triple Negative Breast Cancer
Drug: Sacituzumab govitecan

Phase 3

Unicancer
Unicancer

Villejuif, France

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) (PRESERVE 2)

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo a...

Active, not recruiting
Breast Cancer
TNBC - Triple-Negative Breast Cancer
Drug: Trilaciclib
Drug: Placebo

Phase 3

G1 Therapeutics

Villejuif, France and 70 other locations

A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer (COMPASS-TNBC)

Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer:A phase Ib/II, open-l-...

Enrolling
Breast Cancer
Drug: Durvalumab
Drug: Dato-DXd

Phase 1, Phase 2

Gustave Roussy

Villejuif, France

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) (POP-DURVA)

This study aims to evaluate the efficacy and safety of preoperative Durvalumab in patients with early small (cT1N0) triple negative ...

Enrolling
Early Small (cT1N0) Triple Negative Breast Cancer
Drug: Durvalumab

Phase 2

Gustave Roussy

Villejuif, France and 2 other locations

"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer

Neoadjuvant treatment is an important part of the treatment strategy for locally advanced TNBC having established a positive and significant correlat...

Enrolling
Triple Negative Breast Neoplasms
Combination Product: Atezolizumab + RP1

Phase 1, Phase 2

Institut Curie

Paris, France

A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer (EL1SSAR)

with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not...

Active, not recruiting
Triple-Negative Breast Cancer
Drug: Nab-Paclitaxel
Drug: Atezolizumab

Phase 3

Roche
Roche

Levallois-Perret, France and 75 other locations

Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC (SYNERGY)

a substantial proportion of patients do not derive benefit from this approach.CD73 is an adenosine-generating enzyme overexpressed in several cancers...

Active, not recruiting
Triple Negative Breast Cancer
Drug: MEDI9447
Drug: Carboplatin

Phase 1, Phase 2

Free University of Brussels (ULB)

Paris, France and 15 other locations

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST)

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Placebo
Drug: Niraparib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Saint-Cloud, France and 199 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems